No Data
No Data
Market Chatter: CD&R in Talks With Sanofi For Potential Commitments Package
Jasper Gains 11% on Data for Briquilimab in Urticaria
Hemophilia Markets Poised for Evolution as Competitive Dynamics Between Hemlibra (Roche/Genentech) and Altuviiio (Sanofi) Intensify and Hympavzi (Pfizer) Receives Approval, According to Spherix Global Insights
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
Johnson & Johnson Preps For Q3 Earnings As MedTech Expands, But Stock Sends Mixed Signals
Should Value Investors Buy Sanofi (SNY) Stock?
No Data
No Data